Skip to main content

01.09.2015 | Original Article

Exploring the measurement properties of the Montreal Cognitive Assessment in a population of people with cancer

verfasst von: Giovanni G. Arcuri, Lisa Palladini, Gabrielle Dumas, Josée Lemoignan, Bruno Gagnon

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Cancer and cancer-related treatments are associated with a constellation of physical and psychological changes. Treatments associated with noncentral nervous system neoplasms can have short- and long-term effects on cognition, affecting quality of life in people with cancer. Clinical measurement tools specific to cancer-related mild cognitive impairment (MCI) are lacking. The Montreal Cognitive Assessment (MoCA) has been validated in a geriatric population and used in studies assessing MCI in persons with cancer, but no studies have yet shown its psychometric properties when used with this population.

Purpose

The purpose of this study is to explore the psychometric properties of the MoCA within a population of persons with noncentral nervous system cancer.

Methods

A total of 74 participants were included from persons attending a Cancer Nutrition-Rehabilitation Program at the McGill University Health Centre. Rasch analyses were conducted.

Results

The MoCA data fit all the properties of the Rasch model with a person separation index of 1.04 and person reliability of 0.52. The MoCA items were found to measure a unidimensional construct and spanned 6.57 logits, with item difficulty levels between 2.49 and −4.08 logits. However, the MoCA presented a lack of items of higher difficulty, as person cognitive ability levels ranged from −0.51 to 5.17 logits.

Conclusion

Within the limits of a small sample size, the results of this exploratory study suggest the possibility that the MoCA, when used within a population of persons with cancer, may meet criteria for unidimensionality and adequate item fit but may present weaknesses when used with participants of higher cognitive abilities.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94(1):39–49PubMedCrossRef Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94(1):39–49PubMedCrossRef
4.
Zurück zum Zitat Ahles TA, Root JC, Ryan EL (2012) Cancer-and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 30(30):3675–3686PubMedCentralPubMedCrossRef Ahles TA, Root JC, Ryan EL (2012) Cancer-and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 30(30):3675–3686PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE (2003) Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc: JINS 9(7):967–982. doi:10.1017/S1355617703970019 PubMed Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE (2003) Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc: JINS 9(7):967–982. doi:10.​1017/​S135561770397001​9 PubMed
7.
Zurück zum Zitat Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59(1):60–70. doi:10.1016/j.bandc.2005.05.001 PubMedCrossRef Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59(1):60–70. doi:10.​1016/​j.​bandc.​2005.​05.​001 PubMedCrossRef
8.
Zurück zum Zitat Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E (2006) A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 20(1):76–89. doi:10.1080/138540491005875 PubMedCrossRef Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E (2006) A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 20(1):76–89. doi:10.​1080/​138540491005875 PubMedCrossRef
9.
Zurück zum Zitat Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J (2005) A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104(10):2222–2233. doi:10.1002/cncr.21469 PubMedCrossRef Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J (2005) A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104(10):2222–2233. doi:10.​1002/​cncr.​21469 PubMedCrossRef
10.
Zurück zum Zitat Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, Hussin MG, Jacobsen PB, Small BJ (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 30(29):3578–3587. doi:10.1200/JCO.2011.39.5640 CrossRef Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, Hussin MG, Jacobsen PB, Small BJ (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 30(29):3578–3587. doi:10.​1200/​JCO.​2011.​39.​5640 CrossRef
11.
Zurück zum Zitat Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP (2011) Either called “chemobrain” or “chemofog”, the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manag 41(1):126–139CrossRef Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP (2011) Either called “chemobrain” or “chemofog”, the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manag 41(1):126–139CrossRef
12.
13.
Zurück zum Zitat Bond SM, Dietrich MS, Murphy BA (2012) Neurocognitive function in head and neck cancer patients prior to treatment. Support Care Cancer 20(1):149–157PubMedCrossRef Bond SM, Dietrich MS, Murphy BA (2012) Neurocognitive function in head and neck cancer patients prior to treatment. Support Care Cancer 20(1):149–157PubMedCrossRef
14.
Zurück zum Zitat Vardy J, Wefel J, Ahles T, Tannock I, Schagen S (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19(4):623–629PubMedCrossRef Vardy J, Wefel J, Ahles T, Tannock I, Schagen S (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19(4):623–629PubMedCrossRef
16.
Zurück zum Zitat Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JE, Shahani L, Gritz ER (2011) Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 117(1):190–196. doi:10.1002/cncr.25298 PubMedCrossRef Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JE, Shahani L, Gritz ER (2011) Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 117(1):190–196. doi:10.​1002/​cncr.​25298 PubMedCrossRef
17.
Zurück zum Zitat DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics, 2014. CA: Cancer J Clin 64(4):252–271. doi:10.3322/caac.21235 DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics, 2014. CA: Cancer J Clin 64(4):252–271. doi:10.​3322/​caac.​21235
18.
Zurück zum Zitat Nelson WL, Suls J (2013) New approaches to understand cognitive changes associated with chemotherapy for non-central nervous system tumors. J Pain Symptom Manag 46(5):707–721CrossRef Nelson WL, Suls J (2013) New approaches to understand cognitive changes associated with chemotherapy for non-central nervous system tumors. J Pain Symptom Manag 46(5):707–721CrossRef
19.
Zurück zum Zitat Ganz PA, Kwan L, Castellon SA, Oppenheim A, Bower JE, Silverman DH, Cole SW, Irwin MR, Ancoli-Israel S, Belin TR (2013) Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. Journal of the National Cancer Institute: djt073 Ganz PA, Kwan L, Castellon SA, Oppenheim A, Bower JE, Silverman DH, Cole SW, Irwin MR, Ancoli-Israel S, Belin TR (2013) Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. Journal of the National Cancer Institute: djt073
20.
Zurück zum Zitat Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38(7):926–934PubMedCrossRef Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38(7):926–934PubMedCrossRef
21.
Zurück zum Zitat Vardy J, Rourke S, Tannock IF (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol Off J Am Soc Clin Oncol 25(17):2455–2463. doi:10.1200/JCO.2006.08.1604 CrossRef Vardy J, Rourke S, Tannock IF (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol Off J Am Soc Clin Oncol 25(17):2455–2463. doi:10.​1200/​JCO.​2006.​08.​1604 CrossRef
22.
Zurück zum Zitat Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699PubMedCrossRef Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699PubMedCrossRef
23.
Zurück zum Zitat Olson RA, Chhanabhai T, McKenzie M (2008) Feasibility study of the Montreal Cognitive Assessment (MoCA) in patients with brain metastases. Support Care Cancer 16(11):1273–1278PubMedCrossRef Olson RA, Chhanabhai T, McKenzie M (2008) Feasibility study of the Montreal Cognitive Assessment (MoCA) in patients with brain metastases. Support Care Cancer 16(11):1273–1278PubMedCrossRef
24.
Zurück zum Zitat Olson RA, Iverson GL, Carolan H, Parkinson M, Brooks BL, McKenzie M (2011) Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life. J Neuro-Oncol 105(2):337–344CrossRef Olson RA, Iverson GL, Carolan H, Parkinson M, Brooks BL, McKenzie M (2011) Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life. J Neuro-Oncol 105(2):337–344CrossRef
25.
Zurück zum Zitat Baxter MF, Dulworth AN, Smith TM (2011) Identification of mild cognitive impairments in cancer survivors. Occup Ther Health Care 25(1):26–37PubMedCrossRef Baxter MF, Dulworth AN, Smith TM (2011) Identification of mild cognitive impairments in cancer survivors. Occup Ther Health Care 25(1):26–37PubMedCrossRef
26.
Zurück zum Zitat Koski L, Xie H, Konsztowicz S (2011) Improving precision in the quantification of cognition using the Montreal Cognitive Assessment and the Mini-Mental State Examination. Int Psychogeriatr/IPA 23(7):1107–1115. doi:10.1017/S1041610210002450 CrossRef Koski L, Xie H, Konsztowicz S (2011) Improving precision in the quantification of cognition using the Montreal Cognitive Assessment and the Mini-Mental State Examination. Int Psychogeriatr/IPA 23(7):1107–1115. doi:10.​1017/​S104161021000245​0 CrossRef
29.
Zurück zum Zitat Gagnon B, Murphy J, Eades M, Lemoignan J, Jelowicki M, Carney S, Amdouni S, Di Dio P, Chasen M, MacDonald N (2013) A prospective evaluation of an interdisciplinary nutrition–rehabilitation program for patients with advanced cancer. Curr Oncol 20(6):310PubMedCentralPubMedCrossRef Gagnon B, Murphy J, Eades M, Lemoignan J, Jelowicki M, Carney S, Amdouni S, Di Dio P, Chasen M, MacDonald N (2013) A prospective evaluation of an interdisciplinary nutrition–rehabilitation program for patients with advanced cancer. Curr Oncol 20(6):310PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Linacre JM (2012) Winsteps® Rasch measurement computer program user’s guide. Winsteps.com, Beaverton Linacre JM (2012) Winsteps® Rasch measurement computer program user’s guide. Winsteps.com, Beaverton
31.
Zurück zum Zitat Reckase MD (1979) Unifactor latent trait models applied to multifactor tests: results and implications. J Educ Behav Stat 4(3):207–230CrossRef Reckase MD (1979) Unifactor latent trait models applied to multifactor tests: results and implications. J Educ Behav Stat 4(3):207–230CrossRef
32.
Zurück zum Zitat Linacre J (2014) Winsteps® Rasch measurement computer program. Winsteps.com, Beaverton Linacre J (2014) Winsteps® Rasch measurement computer program. Winsteps.com, Beaverton
33.
Zurück zum Zitat Chou Y-T, Wang W-C (2010) Checking dimensionality in item response models with principal component analysis on standardized residuals. Educ Psychol Meas 70(5):717–731CrossRef Chou Y-T, Wang W-C (2010) Checking dimensionality in item response models with principal component analysis on standardized residuals. Educ Psychol Meas 70(5):717–731CrossRef
34.
Zurück zum Zitat Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 20(2):485–493CrossRef Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 20(2):485–493CrossRef
37.
Zurück zum Zitat Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 15(5):422–430. doi:10.1002/pon.964 PubMedCrossRef Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 15(5):422–430. doi:10.​1002/​pon.​964 PubMedCrossRef
38.
Zurück zum Zitat Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, Verhoeven JS, Christiaens MR, Vandenberghe J, Vandenbulcke M, Sunaert S (2012) Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol Off J Am Soc Clin Oncol 30(3):274–281. doi:10.1200/JCO.2011.36.8571 CrossRef Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, Verhoeven JS, Christiaens MR, Vandenberghe J, Vandenbulcke M, Sunaert S (2012) Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol Off J Am Soc Clin Oncol 30(3):274–281. doi:10.​1200/​JCO.​2011.​36.​8571 CrossRef
39.
Zurück zum Zitat Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinoma. Cancer 100(11):2292–2299PubMedCrossRef Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinoma. Cancer 100(11):2292–2299PubMedCrossRef
40.
Zurück zum Zitat Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348–3356PubMedCrossRef Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348–3356PubMedCrossRef
41.
Zurück zum Zitat Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(5):353–360PubMedCrossRef Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(5):353–360PubMedCrossRef
42.
43.
Zurück zum Zitat Chen W-H, Lenderking W, Jin Y, Wyrwich KW, Gelhorn H, Revicki DA (2014) Is Rasch model analysis applicable in small sample size pilot studies for assessing item characteristics? An example using PROMIS pain behavior item bank data. Qual Life Res 1–9 Chen W-H, Lenderking W, Jin Y, Wyrwich KW, Gelhorn H, Revicki DA (2014) Is Rasch model analysis applicable in small sample size pilot studies for assessing item characteristics? An example using PROMIS pain behavior item bank data. Qual Life Res 1–9
45.
Zurück zum Zitat Raffa R (2013) Cancer ‘survivor-care’: II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment). J Clin Pharm Ther 38(4):265–268PubMedCentralPubMedCrossRef Raffa R (2013) Cancer ‘survivor-care’: II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment). J Clin Pharm Ther 38(4):265–268PubMedCentralPubMedCrossRef
Metadaten
Titel
Exploring the measurement properties of the Montreal Cognitive Assessment in a population of people with cancer
verfasst von
Giovanni G. Arcuri
Lisa Palladini
Gabrielle Dumas
Josée Lemoignan
Bruno Gagnon
Publikationsdatum
01.09.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2643-7

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.